去势抵抗性前列腺癌个体化药物治疗的分析-analysis of individualized drug therapy for castration-resistant prostate cancer.docx

个人简历......................................................................................................................30CRPC 个体化药物治疗的研究摘要目的：探讨个体化化疗药物治疗去势抵抗性前列腺癌（CRPC）的临床效果。方法：采用前瞻性随机对照方法，将 2013 年 2 月至 2014 年 12 月山西医科大学第 一医院泌尿外科收治的 41 例去势抵抗性前列腺癌患者随机分为 2 组。治疗组检 测 TUBB3、ERCC1 基因 mRNA 及 MDR1 基因多态性，根据结果针对性的选择 化疗方案，个体化选用常见的三种化疗药物，包括多西他赛、米托蒽醌、顺铂； 对照组采用以多西他赛为基础的方案治疗；两组患者从血清 TPSA、肿瘤病灶变 化、骨扫描、患者疼痛评分等指标进行比较，每 3 周为 1 个周期，连续治疗 6 个周期后进行评估。结果：（1）治疗后，治疗组血清 TPSA 值为 30.9±5.43，对照组血清 TPSA 值为 39.1±7.7，有统计学意义差异；（2）治疗后，治疗组疼痛评分值为 5.5±0.94，对 照组疼痛评分值为 6.4±1.27，有统计学意义差异；（3）治疗后，治疗组骨扫描 转移病灶与对照组相比，有统计学意义差异；（4）治疗后，治疗组肿瘤病灶与 对照组相比，有统计学意义差异。结论：个体化化疗对 CRPC 患者具有针对性强，疗效好，能使患者生存获益，具有 临床推广价值。关键词：去势抵抗性前列腺癌；个体化；化疗Castration resistant prostate cancer research of individualized drug therapyAbstractObjective:To study the individualized chemotherapy drug castration resistant prostate cancer (CRPC) clinical effect.Methods:Prospective, randomized, controlled method, will in February 2013 to December 2014, shanxi medical university first hospital uropoiesis surgical department of 41 patients with CRPC were randomly divided into 2 groups.Treatment group detection TUBB3, ERCC1 gene mRNA and MDR1 gene polymorphism, according to the results of the choice of targeted chemotherapy regimens, individualized selection of common three kinds of chemotherapy drugs, including his dorsey, mitoxantrone, cisplatin;More than the control group only with west he match treatment;Change from two groups patients serum TPSA, tumor lesions, bone scan, the patient pain score metrics such as comparison, every three weeks for a cycle, continuous assessment after treatment for 6 cycles. cisplatin;More than the control group only with west he match treatment;Change from two groups patients serum TPSA, tumor lesions, bone scan, the patient pain score metrics such as comparison, every three weeks for a cycle, continuous.Results:(1) after treatment, the treatment group serum TPSA value was 30.9 ± 5.43, the control group, serum TPSA value wa